Variant report
Variant | esv3370999 |
---|---|
Chromosome Location | chr16:12669859-12670212 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:0)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
No data |
No data |
No data |
No data |
No data |

No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs545608317 | chr16:12669903-12669904 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
2 | rs61033720 | chr16:12669920-12669921 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
3 | rs200278579 | chr16:12669921-12669922 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
4 | rs4781267 | chr16:12669941-12669942 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
5 | rs369589215 | chr16:12669953-12669954 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
6 | rs4781268 | chr16:12669962-12669963 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
7 | rs538947143 | chr16:12669963-12669964 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
8 | rs374867293 | chr16:12669986-12669987 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
9 | rs368618466 | chr16:12669989-12669990 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
10 | rs187106958 | chr16:12669993-12669994 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
11 | rs569104185 | chr16:12670000-12670001 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
12 | rs539379000 | chr16:12670001-12670002 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
13 | rs549550951 | chr16:12670009-12670010 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
14 | rs569481032 | chr16:12670015-12670016 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
15 | rs148701706 | chr16:12670024-12670025 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
16 | rs554594986 | chr16:12670038-12670039 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
17 | rs4780454 | chr16:12670048-12670049 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
18 | rs11644028 | chr16:12670050-12670051 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
19 | rs201402602 | chr16:12670052-12670053 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
20 | rs369189721 | chr16:12670054-12670055 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
21 | rs146952316 | chr16:12670055-12670056 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
22 | rs563113909 | chr16:12670065-12670066 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
23 | rs4781269 | chr16:12670072-12670073 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
24 | rs11647633 | chr16:12670088-12670089 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
25 | rs574400561 | chr16:12670093-12670094 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
26 | rs191954556 | chr16:12670098-12670099 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
27 | rs181407262 | chr16:12670099-12670100 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
28 | rs577443865 | chr16:12670107-12670108 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
29 | rs546552365 | chr16:12670112-12670113 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
30 | rs563189557 | chr16:12670132-12670133 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
31 | rs78565871 | chr16:12670138-12670139 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
32 | rs185498532 | chr16:12670150-12670151 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
33 | rs553457550 | chr16:12670154-12670155 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
34 | rs371419459 | chr16:12670158-12670159 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
35 | rs190298308 | chr16:12670163-12670164 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
36 | rs547350735 | chr16:12670181-12670182 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
37 | rs555463945 | chr16:12670188-12670189 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
38 | rs547412767 | chr16:12670196-12670197 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
39 | rs148779643 | chr16:12670205-12670206 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
40 | rs141563670 | chr16:12670206-12670207 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
41 | rs182502903 | chr16:12670209-12670210 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
42 | rs549638723 | chr16:12670211-12670212 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Cancer | 21183584 | CNVD |
Follicular lymphoma | 20505157 | CNVD |
High-grade prostatic intraepithelial neoplasia | 16573809 | CNVD |
Prostate cancer | 16573809 | CNVD |
Breast cancer | 17603634 | CNVD |
Hodgkin''s lymphoma | 20651079 | CNVD |
Metanephric adenoma | 20802469 | CNVD |
Melanoma | 18172304 | CNVD |
Breast cancer | 16608533 | CNVD |
Basal cell lymphoma | 16317097 | CNVD |
Diffuse large b-cell lymphoma | 16317097 | CNVD |
Breast cancer | 17133270 | CNVD |
Endometrioid adenocarcinoma | 16974079 | CNVD |
Adenoid cystic carcinoma | 17372589 | CNVD |
Lung adenocarcinoma | 17086460 | CNVD |
Lung cancer | 17086460 | CNVD |
Autism | 22566537 | CNVD |
Intellectual disability | 22566537 | CNVD |
Non-syndromic sensorineural hearing loss | 18471307 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Astrocytoma | 17387387 | CNVD |
Breast cancer | 21264507 | CNVD |
Cervical cancer | 21063398 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Acute lymphoblastic leukemia | 17690704 | CNVD |
Autism | 19415332 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Non-syndromic sensorineural hearing loss | 22037309 | CNVD |
Schizophrenia | 22958593 | CNVD |
Lung cancer | 18438408 | CNVD |
Ductal carcinoma | 22052326 | CNVD |
Breast cancer | 21509527 | CNVD |
Thoracic aortic aneurysm | 21092924 | CNVD |
Autism | 22102821 | CNVD |
Autism | 22495311 | CNVD |
idiopathic generalized epilepsy | 19843651 | CNVD |
T-cell prolymphocytic leukemia | 17713554 | CNVD |
Breast cancer | 20668451 | CNVD |
Cancer | 20668451 | CNVD |
Lung cancer | 20668451 | CNVD |
Ovarian cancer | 20668451 | CNVD |
Pancreas cancer | 20668451 | CNVD |
Prostate cancer | 20668451 | CNVD |
Intellectual disability | 22102821 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Acute lymphoblastic leukemia | 22237106 | CNVD |
low-grade B-cell lymphoma tumor | 18367492 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Malignant peripheral nerve sheath tumor | 18522746 | CNVD |
Prostate cancer | 18632612 | CNVD |
Schizophrenia | 20587603 | CNVD |
Schizophrenia | 20553308 | CNVD |
Autism | 19786961 | CNVD |
Mental retardation | 19786961 | CNVD |
Schizophrenia | 19786961 | CNVD |
Mental retardation | 19951919 | CNVD |
Autism | 18791038 | CNVD |
Splenic marginal zone lymphoma | 18492102 | CNVD |
Malignant germ cell tumour | 17285132 | CNVD |
Autism | 17480035 | CNVD |
Schizophrenia | 19955444 | CNVD |
Breast cancer | 21858162 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Mental retardation | 17847001 | CNVD |
Breast cancer | 22522925 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr16:12613000-12670800 | Weak transcription | Pancreas | Pancrea |
2 | chr16:12652600-12672200 | Weak transcription | Right Ventricle | heart |
3 | chr16:12661800-12670400 | Weak transcription | Primary hematopoietic stem cells G-CSF-mobilized Male | -- |
4 | chr16:12662800-12672000 | Weak transcription | iPS DF 19.11 Cell Line | embryonic stem cell |
5 | chr16:12664000-12670600 | Weak transcription | Gastric | stomach |
6 | chr16:12664600-12670600 | Weak transcription | Skeletal Muscle Male | skeletal muscle |
7 | chr16:12665000-12670600 | Weak transcription | Spleen | Spleen |
8 | chr16:12667800-12670400 | Weak transcription | Primary hematopoietic stem cells short term culture | blood |
9 | chr16:12668000-12670600 | Weak transcription | Primary Natural Killer cells fromperipheralblood | blood |
10 | chr16:12668400-12670200 | Weak transcription | Primary B cells from cord blood | blood |
11 | chr16:12668400-12672400 | Weak transcription | Fetal Intestine Small | intestine |
12 | chr16:12668600-12671000 | Weak transcription | HepG2 | liver |
13 | chr16:12668600-12672200 | Enhancers | Primary B cells from peripheral blood | blood |
14 | chr16:12668800-12670400 | Weak transcription | GM12878-XiMat | blood |
15 | chr16:12669400-12673000 | Weak transcription | Ganglion Eminence derived primary cultured neurospheres | brain |
16 | chr16:12670200-12672000 | Enhancers | Primary B cells from cord blood | blood |